Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 8 25 % varying impact on TDF outcomes

From: Cost-effectiveness analysis of oral anti-viral drugs used for treatment of chronic hepatitis B in Turkey

  Age HBeAg (−) rate (%) TDF: virologic response 48th week in HBeAg (−) (%) TDF: virologic response 48th week in HBeAg (+) (%) TDF annual drug cost (TL)
Base case 40 70 93.2 76.1 2236
25 % increase 50 88 100.0 95.2 2796
25 % decrease 30 53 69.9 57.1 1677